Summary
An investigational anti-interferon-a monoclonal antibody, sifalimumab, reduced global disease activity in patients with systemic lupus erythematosus (SLE). This article presents results from a phase 2b study of sifalimumab in patients with moderate to severe SLE.
- Rheumatology Clinical Trials
 - Lupus
 
- Rheumatology Clinical Trials
 - Rheumatology
 - Lupus
 
- © 2014 MD Conference Express®
 










